Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

Valentina Fanny Leone1, Amantia Imeraj2, Sara Gastoldi2, Caterina Mele2, Lucia Liguori2, Carmelita Condemi1, Piero Ruggenenti1*, Giuseppe Remuzzi2 and Camillo Carrara1

1Unit of Nephrology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy, 2Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy

Hemolytic uremic syndrome (HUS) is a rare life-threatening disease of unrestrained complement system dysregulation, microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure in genetically predisposed individuals. In this report, we describe two cases of SARS-CoV-2–associated HUS treated with eculizumab, a C5-blocking monoclonal antibody reported to be remarkably effective in the treatment of HUS. Detailed biochemical and genetic complement system analysis is reported, and the prompt clinical response after C5 pharmacological blockade is documented. Our report provides the rationale and supports the use of terminal complement pathway inhibition for the treatment of SARS-CoV-2–associated HUS.

Keywords: eculizumab, coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2), thrombotic microangiopathy, hemolytic uremic syndrome

INTRODUCTION

Over 270 million people have been infected globally with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and over 5 million have died from coronavirus disease (COVID-19) since the first cases were detected in the city of Wuhan, China (https://coronavirus.jhu.edu/map.html, 2021). SARS-CoV-2 invades the alveolar cells in the lungs, which is the virus’ portal of entry, and then it spreads to the rest of the body, causing, in most severely ill patients, multiorgan involvement and damage (Guan et al., 2020). Accumulating evidence indicates that the mechanisms of COVID-19–associated tissue injury are not primarily mediated by viral infection but rather are the result of the host immune response, which drives hypercytokinemia and inflammation (Chen et al., 2020).

Unrestrained complement system activation is emerging as a key factor of endothelial dysfunction, thrombosis, and organ damage in patients with COVID-19 (Afzali et al., 2021; Aiello et al., 2021).

In particular, increased levels of C5a and strong deposits of C5b-9 have been detected respectively in the serum, lung parenchyma, and vessels of COVID-19 patients, highlighting the role of the complement terminal pathway in the critical phase of the viral infection (Diao et al., 2021)(Carvelli et al., 2020). Higher baseline plasma concentrations of C3a and sC5b-9 were observed in COVID-19 patients experiencing a thromboembolic event, and sC5b-9 concentrations correlated with D-dimer...
levels (de Nooijer et al., 2021). Furthermore, fibrin and intense C5b–9 immunostaining were found in the kidney glomeruli and cardiac microthrombi (Pfister et al., 2020; Pellegrini et al., 2021).

The C5 complement-blocker eculizumab proved to be an effective weapon in complement-related disorders and radically improved outcomes of patients with atypical hemolytic uremic syndrome (HUS) (Gruppo and Rother, 2009; Legendre et al., 2013; Noris et al., 2012). These evidences provided the rationale for studies evaluating the potential therapeutic effect of complement inhibition by the C5 blocker eculizumab in patients with COVID-19 (Annan et al., 2020). It is to be noted that a recent cohort study in patients with severe COVID-19 showed that complement inhibition was associated with prompt improvement in respiratory dysfunction and decreased the combined endpoint of long-term mortality and chronic complications as compared to contemporary similar controls (Ruggenenti et al., 2021). However, other studies failed to demonstrate a clinical benefit of C5 inhibition (https://ir.alexion.com/news14releases/news-release-details/ alexion-provides-update-phase-3-study-ultomiris-ravulizumab). Conceivably, eculizumab should prove to be even more effective in COVID-19 patients with genetically determined abnormalities in the complement system (as in atypical HUS) and those who present with clinical features of thrombotic microangiopathy (TMA) characterized by the triad of thrombocytopenia, microangiopathic hemolytic anemia, and evidence of organ injury. HUS has been exceptionally reported in association with COVID-19 (Jhaveri et al., 2020; Mat et al., 2021; Safak et al., 2021; Ville et al., 2021; Boudhabhay et al., 2021).

It could be hypothesized that SARS-CoV-2 may act as a trigger of complement activation in genetically predisposed individuals, as occurs in complement-associated HUS and occasional cases of Shiga toxin–producing Escherichia coli–associated HUS (STEC-HUS) (Alberti et al., 2013).

Here, we describe two additional patients infected with SARS-CoV-2 who developed HUS. Biochemical and genetic complement system studies and the rapid clinical response after C5 pharmacological blockade support the use of eculizumab in this setting.

## CASE PRESENTATION

### Patient 1

A 77-year-old female with a history of arterial hypertension, rheumatoid arthritis, and chronic hepatitis B presented to our emergency department after a 10-day history of asthenia, vomiting, and progressive oliguria. At presentation, she was afibrile, and arterial blood pressure was in good control. Clinical examination of the lungs was relevant for diffuse bilateral crackles, while the rest of general examination was unremarkable. She was then admitted to the Infectious Disease Unit.

Chest X-ray showed interstitial bilateral opacities, suggesting SARS-CoV-2 interstitial pneumonia. The diagnosis of SARS-CoV-2 infection was confirmed by a nasopharyngeal swab on real-time reverse transcription polymerase chain reaction (RT-PCR). Laboratory tests at presentation revealed acute renal failure, while blood count was normal and C-reactive protein (CPR) only mildly elevated. From day 3, the patient developed severe anemia and thrombocytopenia with positive markers of intravascular hemolysis, such as increase of lactate dehydrogenase and haptoglobin consumption, with a few schistocytes that were evidenced in the blood smear (Table 1).

| Variable (pre eculizumab)       | Patient 1 | Patient 2 |
|---------------------------------|-----------|-----------|
| White cell count (per μl)       | 12,460    | 6,790     |
| Red cell count (per μl)         | 2,620     | 2,960     |
| Hemoglobin (g/dl)               | 7.8       | 9         |
| Hematocrit (%)                  | 21.3      | 27.2      |
| Platelet count (per μl)         | 56,000    | 99,000    |
| Creatinine (mg/dl)              | 9.43      | 5.88      |
| Urea nitrogen (mg/dl)           | 204       | 212       |
| Sodium (mmol/L)                 | 147       | 150       |
| Total bilirubin (mg/dl)         | 0.7       | 1         |
| Aspartate aminotransferase (U/liter) | 8     | 47       |
| Alanine aminotransferase (U/liter) | 13   | 16       |
| D-dimer                         | 2,234     | 2056      |
| Prothrombin time (PT) (ratio)   | 1.13      | 1.88*     |
| Activated partial thromboplastin time (ratio) | 1.18  | 1.55     |
| Lactate dehydrogenase (U/liter) | 548     | 1758      |
| Haptoglobin                     | 0.04      | <0.01     |
| Schistocytes                    | Rare      | Rare      |
| C-reactive protein (mg/dl)      | 9.4       | 11.5      |
| C3 (mg/dl)                      | 81        | 72        |
| C4 (mg/dl)                      | 21        | 19        |
| Ab anti-ADAMTS13 (U/ml)         | 7         | 7         |
| ADAMTS 13 inhibitory activity   | Negative  | Negative  |
| Coombs’ test                    |          |          |
| Antinuclear antibodies (ANAs)   | Negative  | Negative  |
| Anti-DNA                        | Negative  | NA        |
| Extractable nuclear antigen antibodies (ENAs) | Negative | NA        |

D-dimer was markedly elevated, while prothrombin (PT) and partial thromboplastin time (PTT) were normal and Coombs test negative. ADAMTS13 activity was normal with no ADAMTS13 inhibitor autoantibodies identified. Heparin-induced antibodies tested negative. There was no C3 or C4 hypocomplementemia. The genetic assessment of complement regulatory genes and ADAMTS13 through next-generation sequencing (NGS) was negative, and no risk haplotypes were found, although an heterozygous variant of unknown significance (VUS) was identified in the CFHR4 gene (the synonymous variant c.1234C > A, p.Arg412Arg, maxAF 0.0031 in gnADgen_OTH), which is predicted (by Human Splicing Finder) to potentially alter splicing by activating a cryptic splice acceptor site. Additional genetic analyses, conducted through multiplex ligation–dependent probe amplification (MLPA), revealed the polymorphic heterozygous deletion of CFHR3/CFHR1 genes.

Due to worsening respiratory failure, the patient was treated with oxygen therapy through nasal cannula and a course of pulse and then oral steroids and large spectrum antibiotic therapy was initiated. Anticoagulant therapy with heparin, which was rapidly initiated at the time of patient admission, was discontinued on
day 3 due to worsening thrombocytopenia. Supportive care management of acute renal failure being ineffective, renal replacement therapy was started on day 2. On day 8, after admission, the patient was treated with eculizumab (900 mg) (Figure 1A).

The blood tests showed prompt improvement of platelet count and normalization of hemolysis parameters. Hemodialysis was stopped on day 20, given the amelioration of kidney function and urine output. The respiratory insufficiency gradually resolved. The patient was discharged on day 39 in good clinical conditions but with mild residual renal dysfunction (serum creatinine 2.47 mg/dL). Plasma levels of the terminal complement complex sC5b-9 measured 3 months after onset were normal (157 ng/ml, n.v. <300 ng/ml).

**Patient 2**

A 79-year-old female with a past history of valvular heart disease, initial cerebral vasculopathy, and stage IV chronic kidney disease (CKD) presented to our emergency department with low-grade fever, shortness of breath, oliguria, and gross hematuria. Arterial blood pressure was only mildly elevated. The pulse oximeter demonstrated moderate hypoxemia. She was then admitted to the Infectious Disease Unit.

Initial laboratory tests showed severe anemia, elevated CRP, and modest elevation of D-dimer. Infection by SARS-CoV-2 was confirmed by RT-PCR performed on nasal swab. Chest X-ray revealed bilateral accentuation of the pulmonary interstitium. Diffuse "ground glass" opacities were confirmed at a subsequent chest CT-scan. A renal ultrasonogram showed reduced kidney
size with thinned cortical thickness. On day 11, a cerebral CT scan was performed due to a confusional state and an absence episode with slight deviation of the left buccal rim. However, no recent parenchymal density alterations were found.

From day 21, laboratory tests demonstrated signs of microangiopathic hemolysis with down-trending platelets and hemoglobin, elevation of lactate dehydrogenase, undetectable haptoglobin levels, and presence of schistocytes on blood smear (Table). ADAMTS13 activity was normal, with no ADAMTS13 inhibitor autoantibodies identified. There was moderate C3 hypocomplementemia with C4 being in the normal range. The plasma levels of sC5b-9 were very elevated (1,190 ng/ml). Marked C5b-9 deposition was found on the microvascular endothelial cells (247% on resting and 267% on activated endothelial cells, normal values < 150%) (Noris et al., 2014) (Figure 2). The genetic assessment of complement regulatory genes through NGS revealed a heterozygous rare missense variant in the gene encoding C3 (c.26T > C that causes the p. Leu9Pro, max AF 0.001 in ExAC_NFE), that is predicted to be likely pathogenetic in silico (CADD 20), as well as the heterozygous H3 risk haplotype in the gene encoding CFH. MLPA analyses on CFH/CFHR genes did not reveal any abnormality.

The patient was treated with intravenous steroids, furosemide, and empiric antibiotic therapy. Oxygen therapy was initiated through nasal cannulas. Anticoagulant therapy with heparin was administered. Due to progressive worsening of renal function with anuria, renal replacement therapy was initiated on day 8. A single dose of 900 mg eculizumab was given on day 27 shortly after the appearance of signs of TMA (Figure 1B). After eculizumab administration, laboratory work-up showed progressive elevation of platelets, hemoglobin levels, and disappearance of schistocytes from the blood smear. Detailed complement testing was again performed 10 days after eculizumab infusion and evidenced the normalization of C5b-9 deposition on the microvascular endothelial cells (Figure 2). The control chest X-ray performed on day 32 showed initial (but not complete) improvement of the lung interstitium. Control nasopharyngeal swabs were performed on days 28 and 30 with negative results. Unfortunately, renal function failed to recover,
and the patient was discharged (day 45) still on renal replacement therapy.

**DISCUSSION**

Here, we present the cases of two patients infected by SARS-CoV-2, who developed severe hemolytic anemia and worsening renal failure in the context of HUS. The patients were both treated with a single dose of eculizumab without concomitant therapeutic plasma exchanges. The use of the C5-inhibitor monoclonal antibody resulted in the progressive improvement of hematological parameters in both patients. On the other hand, while renal replacement therapy could be stopped in Patient 1 due to improving kidney function, Patient 2, who had previous evidence of stage IV CKD, remained dialysis-dependent. Due to the critical conditions and rapidly evolving clinical scenario, Patient 1 was treated empirically with eculizumab as soon as the diagnosis of HUS was established. Conversely, inspired by the favorable course of the first case, we set up a protocol aimed at understanding the potential mechanisms of SARS-CoV-2–associated HUS and therapeutic effect of C5 pharmacological blockade, which we have successfully applied to Patient 2 (Figure 2). During the active phase of the disease, we were able to demonstrate higher than normal C5b-9 and thrombi deposition on the microvascular endothelial cells in Patient 2, which completely normalized after treatment with eculizumab. Genetic analysis revealed a heterozygous variant of unknown significance in the CFHR4 gene and polymorphic heterozygous deletion of CFHR3/CFHRI genes in Patient 1 and detected a rare variant in the gene encoding for C3, considered likely pathogenic, as well as the H3 risk haplotype in the gene encoding for CFH in Patient 2. Thus, in both cases, we found genetic abnormalities in the complement system that could predispose to the development of HUS upon exposure to potential triggers such as certain infectious agents, drugs, or pregnancy (Noris et al., 2012).

HUS represents a clinical manifestation of TMA. It is a rare life-threatening syndrome which results from platelet adhesion to the vascular endothelium and their aggregation and activation with formation of platelet thrombi in the microvasculature, leading to consumptive thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure (Remuzzi, 1987). STEC-HUS, also called typical HUS, is the most frequent form of infection-associated HUS (Johannes and Römer, 2010). The toxin produced by the bacteria triggers endothelial complement deposition through the upregulation of P-selectin and possibly interferes with the activity of complement regulatory molecules. In addition, complement activation has been evidenced in children with STEC-HUS, in terms of higher plasma levels of the alternative complement activation products, such as C3b, C3c, C3d, and increased levels of C5 convertase and of the terminal complement complex sC5b-9 (Thurman et al., 2009; Ferraris et al., 2015; Westra et al., 2017).

In atypical HUS, instead, complement activation occurs as a consequence of genetic dysregulation of the complement alternative pathway (Noris and Remuzzi, 2009). In most cases, however, a trigger is required to develop disease manifestations. Environmental hits are likely to induce endothelial perturbation and complement activation, which in healthy individuals are self-limiting as a result of multiple, redundant, regulatory mechanisms (Noris et al., 2012). An individual with genetic abnormalities affecting complement regulation is particularly vulnerable to complement attack. Once the complement cascade is activated beyond a critical threshold, C3b formation and deposition occur on the vascular endothelium, which leads to further complement activation through the alternative pathway self-amplifying loop, culminating in microangiopathic injury and thrombosis. Reports from large cohorts show that atypical HUS onset or relapse are often triggered by bacterial and viral infections (Fang et al., 2008; Noris et al., 2010), as well as the occurrence of HUS in COVID-19 patients (El Sissy et al., 2021; Mat et al., 2021), and present data corroborate the hypothesis that SARS-CoV-2 triggers the development of renal TMA through activation of the complement alternative pathway.

The clinical manifestation of SARS-CoV-2–associated HUS, which is an extremely rare complication of SARS-CoV-2 infection (Jhaiveri et al., 2020; Mat et al., 2021; Safak et al., 2021; Ville et al., 2021; Boudhabhay et al., 2021), should not be confounded with the much more common systemic coagulopathy that is frequently observed in patients with COVID-19 (Zhou et al., 2020; Tang et al., 2020; Wu et al., 2020). The coagulopathy related to COVID-19 may resemble several systemic coagulation disorders seen in other severe infections, such as disseminated intravascular coagulation (Gando et al., 2016; Levi and Thachil, 2020). Nevertheless, the clinical presentation and laboratory features, at a closer look, may be distinctly different. The prothrombotic state in COVID-19 coagulopathy is associated with high incidence of venous thromboembolism with few hemorrhagic complications in the absence of a real consumptive coagulopathy (Levi and Thachil, 2020). Changes in hemostatic parameters, represented by increase in D-dimer and fibrin/fibrinogen degradation products, indicate that the essence of SARS-CoV-2–related coagulopathy is massive fibrin formation. In comparison with bacterial sepsis–associated disseminated intravascular coagulation, prolongation of PT time is less frequent, and thrombocytopenia is uncommon in COVID-19 (Iba et al., 2020). In addition, histopathology from postmortem samples of COVID-19 patients typically shows microvascular platelet-rich thrombi limited to the small vessels of the lungs (Fox et al., 2020). In summary, SARS-CoV-2 coagulopathy appears to be largely dependent on the severity of endothelial damage triggered by the viral infection and may potentially affect any patient with severe COVID-19. Conversely, SARS-CoV-2–associated HUS is an extremely less frequent complication of SARS-CoV-2 infection that requires a genetic predisposition to result into clinically relevant endothelial damage and TMA (Noris et al., 2020).

The evidence that complement blockade effectively controls microangiopathy and thrombus formation in atypical HUS, together with the demonstration of complement activation during STEC-HUS, has led to the first attempts of eculizumab use in STEC-HUS, although no systematic assessment of its
efficacy in this specific form of HUS is yet available (Walsh and Johnson, 2019). The good outcome of severe STEC-HUS cases treated with eculizumab provided the rationale for its use in COVID-19–associated HUS (Jha et al., 2020; Mat et al., 2021; Safak et al., 2021; Ville et al., 2021; Boudhabhay et al., 2021).

The main limitation of our study is the lack of the ex vivo test of C5b-9 and thrombi deposition on microvascular endothelial cells for Patient 1. Efficacy of eculizumab in COVID-19–associated HUS needs to be confirmed in larger series of patients.

In conclusion, our case report emphasizes the importance of monitoring parameters of hemolysis in patients with COVID-19 to act promptly in the event that HUS develops during the disease. Once HUS is evidenced, we encourage considering complete genetic and biochemical complement system assessment, if possible. Eculizumab, however, should be started as soon as the clinical diagnosis of SARS-CoV-2–associated HUS is established, before target organs are irreversibly damaged by the microangiopathic process. Treatment with the C5-blocker, already validated in HUS and being studied in COVID-19, may play a pivotal role in those rare cases of COVID-19–associated HUS.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

PR and GR had the original idea, VL and CC wrote the first draft and the final version of the manuscript, AI collected all clinical and laboratory data and prepared the table and figures, SG, CM, and LL performed the complement tests and genetic analysis, and VL and AI supervised the eculizumab infusions. CC clinically managed the patients, organized the dialysis sessions, and helped collecting the data. All authors critically revised the first draft of the manuscript and approved the last version for submission.

FUNDING

The present study was funded internally.

ACKNOWLEDGMENTS

We thank Marina Noris and Miriam Galbusera who supervised the complement tests and helped prepare the manuscript. We also thank the medical staff and nurses of the Infectious Disease Unit of Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII for taking care of the two patients with great dedication. We thank the nurses of the Nephrology Unit of Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII for performing the dialysis sessions. We also thank the European Reference Network for Rare Kidney Diseases (ERKNet) of which we are proud members.

REFERENCES

Aftahi, B., Noris, M., Lambrecht, B. N., and Kemper, C. (2021). The State of Complement in COVID-19. Nat. Rev. Immunol. 22, 77–84. doi:10.1038/s41577-021-00665-1

Aiello, S., Gastoldi, S., Galbusera, M., Ruggenenti, P., Portalupi, V., Rota, S., et al. (2022). C5a and C5aR1 Are Key Drivers of Microvascular Platelet Aggregation in Clinical Entities Spanning from aHUS to COVID-19. Blood Adv. 6, 866–881. doi:10.1182/bloodadvances.2021005246

Alberti, M., Valoti, E., Piras, R., Bresin, E., Galbusera, M., Tripodo, C., et al. (2013). Two Patients with History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. Am. J. Transpl. 13, 2201–2206. doi:10.1111/ajt.12297

Annane, D., Heming, N., Grimaldi-Bensouda, L., Frémeaux Bacchi, V., Vigan, M., Roux, A. L., et al. (2020). Eculizumab as an Emergency Treatment for Adult Patients with Severe COVID-19 in the Intensive Care Unit: A Proof-Of-Concept Study. EClinicalMedicine 28, 100590. doi:10.1016/j.eclinm.2020.100590

Boudhabhay, I., Rabant, M., Roumenina, L. T., Coupry, L. M., Poillerat, V., Marchal, A., et al. (2021). Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Front. Immunol. 12, 680567. doi:10.3389/fimmu.2021.680567

Carrelli, J., Demaria, O., Vély, F., Batista, L., Chouaki Benmansour, N., Fares, J., et al. (2020). Association of COVID-19 Inflammation with Activation of the C5a-C5aR1 axis. Nature 588, 146–150. doi:10.1038/s41586-020-2600-6

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., et al. (2020). Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. J. Clin. Invest. 130, 2620–2629. doi:10.1172/JCI137244

Coronavirus Resource Center (2021). Johns Hopkins University of Medicine Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University [JHU]. Available at: https://coronavirus.jhu.edu/map.html Accessed January 3, 2022.

Carvelli, J., Demaria, O., Vély, F., Batista, L., Chouaki Benmansour, N., Fares, J., et al. (2020). Association of COVID-19 Inflammation with Activation of the C5a-C5aR1 axis. Nature 588, 146–150. doi:10.1038/s41586-020-2600-6

Diao, R., Wang, C., Wang, R., Feng, Z., Zhang, J., Yang, H., et al. (2021). Human Kidney Is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Nat. Commun. 12, 2506. doi:10.1038/s41467-021-22781-1

El Sissy, C., Saldman, A., Zanetta, G., Martins, P. V., Poulin, C., Cauchois, R., et al. (2021). COVID-19 as a Potential Trigger of Complement-Mediated Atypical HUS. Blood 138, 1777–1782. doi:10.1182/blood.2021012752

Fang, C. J., Frémeaux-Bacchi, V., Liszewski, M. K., Pianetti, G., Noris, M., Goodship, T. H., et al. (2008). Membrane Cofactor Protein Mutations in Atypical Hemolytic Uremic Syndrome (aHUS), Fatal Stx-HUS, C3
